{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-043869","form_type":"8-K","ticker":"BOLT","cik":"0001641281","company_name":"Bolt Biotherapeutics, Inc.","filed_at":"2025-03-24T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.275392+00:00","generated_at":"2026-05-24T06:37:23.120090+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"medium","headline":"Bolt Biotherapeutics Q4 2024 loss from ops $16.9M; cash $70.2M; BDC-4182 starts trial Q2 2025","bullets":["Q4 2024 loss from operations $16.9M vs $19.8M in Q4 2023; full-year loss $73.0M vs $76.2M.","Collaboration revenue Q4 $7.7M (up from $2.1M Q4 2023); full year $7.7M (down from $7.9M).","Cash $70.2M expected to fund key milestones and operations through mid-2026.","BDC-4182 on track to start Phase 1 trial in gastric cancer in Q2 2025.","BDC-3042 Phase 1 fully enrolled at highest dose; no DLTs; data update expected Q2 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-043869","json":"https://secwatch.observer/filing/0000950170-25-043869.json","markdown":"https://secwatch.observer/filing/0000950170-25-043869.md","text":"https://secwatch.observer/filing/0000950170-25-043869.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1641281/000095017025043869/0000950170-25-043869-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1641281/000095017025043869/bolt-20250324.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T06:37:23.120090+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}